Dear Sir/Madam, Pursuant to Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prism Medico and Pharmacy Ltd has submitted its Annual Report for FY 2024-2025 to BSE and MSEI along with the notice for its 23rd Annual General Meeting scheduled for September 30, 2025 at 11:30 AM via video conferencing. Revenue from operations collapsed sharply from Rs. 292.52 lakhs in FY23-24 to just Rs. 63.19 lakhs in FY24-25, a decline of roughly 78%. The company reported a net loss of Rs. 4.87 lakhs (vs Rs. 2.14 lakhs loss last year) and the Board has not recommended any dividend. The company is also seeking shareholder approval to ratify the appointment of new statutory auditor M/s Garg Mendiratta & Associates (replacing M/s Harjeet Parvesh & Co, which resigned in July 2025) and to approve related party transactions of up to Rs. 60 crores with promoter-linked entities.
Sharp revenue decline, widening losses, and no dividend are negative signals for shareholders. The change of statutory auditor and the sizable related party transaction request (Rs. 60 crores) merit careful review by investors ahead of the AGM.